Pharmaceutical

Regeneron and Mammoth team up to develop gene editing therapies

Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.

Apr 27, 2024 - 00:00
Regeneron and Mammoth team up to develop gene editing therapies
Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.
Read the original article

Tags:

Previous Article

Multiply Labs and GenScript partner on cell isolation automation

Next Article

AstraZeneca posts $2.18bn profit after tax in Q1 2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: AstraZeneca buys early-stage gene therapies from Pfizer in boon for struggling field

STAT+: AstraZeneca buys early-stage gene therapies from...

Jul 28, 2023

Recursion and Exscientia merge to form drug discovery company

Recursion and Exscientia merge to form drug discovery c...

Aug 11, 2024

Opzelura by Incyte for Chronic Cutaneous Lupus Erythema...

May 17, 2024